Research programme: eye disorders antisense therapeutics - UGISense
Latest Information Update: 10 Feb 2023
At a glance
- Originator UGISense
- Class Antisense elements; Eye disorder therapies; Peptide nucleic acids
- Mechanism of Action Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Eye disorders
Most Recent Events
- 05 Jan 2023 UGISense has patent protection for its UgimersTM technology platform before January 2023 (UGISense pipeline, January 2023)
- 05 Jan 2023 Early research in Eye disorders in Germany (Parenteral) before January 2023 (UGISense pipeline, January 2023)